Anlon Healthcare IPO Subscription Status

The Anlon Healthcare IPO witnessed strong demand and was fully subscribed 7.12 times on its final day, 29th August 2025 (till 5:00 PM).

• Qualified Institutional Buyers (QIBs): 1.07x
• Non-Institutional Investors (NIIs): 10.61x
• Retail Individual Investors (RIIs): 47.26x

By the end of the last day, the IPO received bids for 9,47,08,360 shares against the total issue size of 1,33,00,000 shares, signaling a very positive response from investors across categories.

Day-wise subscription trend:

• Day 1 (27th August 2025): 1.69x
• Day 2 (28th August 2025): 3.30x
• Day 3 (29th August 2025): 7.12x

This steady rise in demand shows how investor confidence strengthened as the IPO progressed.

About Anlon Healthcare Limited

Founded in 2013, Anlon Healthcare Limited is a rapidly growing specialty chemical and pharmaceutical company. The company is primarily engaged in:

1. High-purity advanced pharmaceutical intermediates used in the production of Active Pharmaceutical Ingredients (APIs).
2. Manufacturing of APIs themselves, which are essential for producing medicines such as tablets, capsules, syrups, ointments, and nutraceutical products.

Its diverse product portfolio covers:

• Pharmaceutical intermediates
• APIs
• Nutraceutical APIs
• Ingredients for personal care and veterinary use

A notable highlight is that Anlon Healthcare is one of the few Indian manufacturers of Loxoprofen Sodium Dihydrate, a pain management API widely prescribed for arthritis, frozen shoulder, toothache, post-surgery recovery, and back pain relief.

As of January 31, 2025, the company employed 105 staff members (excluding trainees) and 8 contract workers. The R&D pipeline includes:

• 65 commercialized products
• 28 products at pilot stage
• 49 in laboratory development

This extensive pipeline highlights the company’s innovation-driven growth strategy.

Anlon Healthcare Financial Performance

Despite revenue fluctuations, Anlon Healthcare has shown resilience and profitability:

• Revenue (FY 2023): ₹113.12 crore
• Revenue (FY 2024): ₹66.69 crore
• Net Profit (FY 2023): ₹5.82 crore
• Net Profit (FY 2024): ₹9.66 crore

While revenues dipped due to lower API exports in FY 2024, the company managed to improve profitability thanks to cost optimization and better demand for specialty intermediates. Its EBITDA margin also improved, showing efficiency in operations.

Anlon Healthcare IPO GMP

As of Friday, 29th August 2025, the Grey Market Premium (GMP) for Anlon Healthcare IPO stood at ₹6 per share.

This suggests the IPO shares are trading at ₹97 in the grey market, compared to the issue price of ₹91, reflecting a premium of 6.6%.

Market experts note that the high oversubscription in the retail category (47.26x) combined with a positive GMP could lead to a strong listing performance, especially given the company’s niche positioning in pharmaceutical intermediates and APIs.